News
Andexxa Approved for Reversing Anticoagulant Activity of Rivaroxaban, Apixaban
Andexxa, a recombinant modified human Factor Xa (FXa) protein, was approved under the FDA's Accelerated Approval pathway.
Your search for apixaban returned 11 results
AHA 2017 Scientific Sessions
Does Use of Apixaban With Cardiac P-gp Inhibitors Up Bleeding Risk?
Apixaban is a substrate of P-glycoprotein and P-glycoprotein inhibition increases drug exposure.
News
Intracranial Bleed Risk Compared for Apixaban, Warfarin in A-fib Patients
Patients taking apixaban showed significantly less intracranial hemorrhage (0.33% per year) vs. patients taking warfarin (0.80% per year) no matter the type and location.
News
Is Apixaban an Appropriate Alternative to Warfarin in Patients with Severe Renal Impairment?
Findings from a study published in the British Journal of Clinical Pharmacology showed that apixaban appeared to be an appropriate alternative to warfarin for patients with severe renal impairment.
AHA 2015
Apixaban Efficacy, Safety Evaluated in AF Patient on Multiple Concomitant Medications
Older patients, females, and those with comorbidities were more likely to be on multiple medications.
News
FDA Approval Expands Access to Factor Xa Inhibitor Antidote Andexxa
Andexxa was initially granted accelerated approval in May 2018 for patients treated with rivaroxaban or apixaban, when reversal of anticoagulation was needed due to life-threatening or uncontrolled bleeding.
News
Labeling for Several HIV Meds Updated to Include Interaction Data With DOACs
If Tybost is given with atazanavir or darunavir, coadministration with rivaroxaban is not recommended due to a potentially increased bleeding risk.
ACC.18
Interim Data Show Andexanet Alfa Rapidly Reverses Anti-Factor Xa Activity
ANNEXA-4 is a global, single-arm, open-label clinical trial designed to evaluate andexanet alfa in patients who present with an acute major bleed while receiving apixaban, rivaroxaban, edoxaban or enoxaparin.
News
Comparison of Oral Anticoagulants for Preventing Stroke in AF
The greatest risk reduction of stroke or systemic embolism was seen with dabigatran 150mg twice daily (odds ratio [OR] 0.65, 95% CI: 0.52-0.81), followed by apixaban 5mg twice daily (OR 0.79, 95% CI: 0.66-0.94).
AHA 2017 Scientific Sessions
Direct Oral Anticoagulant Use Increasing in Dialysis Patients With AFib
End-stage renal disease patients on dialysis with atrial fibrillation are at high risk for thrombotic complications.
